We are live on ! Find out more
ENGNW icon

enGene Therapeutics Warrants
ENGNW

24 hedge funds and large institutions have $6.26M invested in enGene Therapeutics Warrants in 2023 Q4 according to their latest regulatory filings, with 24 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
24
Holders Change
+24
Holders Change %
–
% of All Funds
0.35%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
24
Increased
–
Reduced
–
Closed
–
Calls
$632K
Puts
–
Net Calls
+$632K
Net Calls Change
+$632K

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$727K
2
BOCH
Blue Owl Capital Holdings
New York
+$365K
3
OFM
Omega Fund Management
Massachusetts
+$365K
4
Calamos Advisors
Calamos Advisors
Illinois
+$192K
5
SCM
Saba Capital Management
New York
+$177K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
FIS
1
FCPM III Services
Netherlands
$2.45M +$2.98M +3,878,148 New
BI
2
BVF Inc
California
$804K +$727K +945,402 New
HCM
3
Highbridge Capital Management
New York
$697K – – –
BOCH
4
Blue Owl Capital Holdings
New York
$404K +$365K +475,077 New
OFM
5
Omega Fund Management
Massachusetts
$404K +$365K +475,077 New
SCM
6
Saba Capital Management
New York
$271K +$177K +230,470 New
Calamos Advisors
7
Calamos Advisors
Illinois
$213K +$192K +250,000 New
PAMP
8
Polar Asset Management Partners
Ontario, Canada
$210K +$139K +180,723 New
CAC
9
Cowen and Company
New York
$118K +$107K +138,712 New
AA
10
AQR Arbitrage
Connecticut
$108K +$97.9K +127,339 New
TCM
11
Tenor Capital Management
New York
$99.2K +$89.7K +116,666 New
D.E. Shaw & Co
12
D.E. Shaw & Co
New York
$89K +$80.5K +104,722 New
PC
13
Periscope Capital
Ontario, Canada
$85K +$76.9K +100,000 New
ACM
14
Atalaya Capital Management
New York
$56.7K +$51.2K +66,666 New
SCM
15
Shaolin Capital Management
Florida
$42.5K +$38.4K +50,000 New
ETH
16
Exos TFP Holdings
New York
$30.2K +$27.3K +35,491 New
KL
17
KIM LLC
Kansas
$28.3K +$25.6K +33,333 New
WA
18
Whitebox Advisors
Minnesota
$28.3K +$25.6K +33,333 New
AC
19
Aristeia Capital
Connecticut
$28.3K +$18.5K +24,045 New
CS
20
Clear Street
New York
$24.1K +$21.8K +28,410 New
CL
21
CSS LLC
Illinois
$22.9K +$20.8K +27,000 New
State of Wisconsin Investment Board
22
State of Wisconsin Investment Board
Wisconsin
$20K +$18.1K +23,570 New
SC
23
Sculptor Capital
New York
$13.3K +$8.69K +11,300 New
Walleye Capital
24
Walleye Capital
New York
$9.52K +$8.61K +11,200 New
WAM
25
Wolverine Asset Management
Illinois
$4.79K +$4.33K +5,633 New

ENGNW Hedge Fund Activity: Q4 2023 in Review

24 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in enGene Therapeutics Warrants (ENGNW) for Q4 2023, worth a combined $6.26M.

Buyers outnumbered sellers: 24 funds opened new ENGNW positions and 0 closed out — a net gain of 24 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was BVF Inc, opening a new position worth an estimated $727K.

  • 24 institutional investors held enGene Therapeutics Warrants (ENGNW) as of Q4 2023, up from 0 in Q3 2023.
  • Funds reported $6.26M of enGene Therapeutics Warrants stock for Q4 2023.
  • 24 funds opened new enGene Therapeutics Warrants positions in Q4 2023 and 0 closed out, a net change of +24 holders.
  • The largest enGene Therapeutics Warrants buyer in Q4 2023 was BVF Inc, an estimated $727K added.

Based on aggregated 13F filings for Q4 2023.